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Abstract 
Review on pancreatic tumors with data on clinics, and 
the genes implicated. 
Classification 
Note 
The classification system here is adapted from those 
outlined in both the AFIP Atlas of Tumor Pathology 
Fourth Series (2007) and WHO Classification of 
Tumors of the Digestive System (2010). Pancreatic 
tumors can be subdivided on various criteria, such as 
their gross features (i.e., solid vs. cystic), anatomic 
location (i.e., intraductal), histogenesis (i.e., epithelial 
vs. non-epithelial) or clinical behavior. 
Classification 
Epithelial tumors 
Cystic 
Serous neoplasms 
- Serous cystadenoma 
-- Microcystic serous cystadenoma 
-- Macrocystic serous cystadenoma 
-- Solid serous cystadenoma 
- Von Hippel-Landau (VHL)-associated serous cystic 
neoplasm 
- Serous cystadenocarcinoma 
Mucinous cystic neoplasm (MCN) 
- MCN with low or intermediate grade dysplasia 
- MCN with high grade dysplasia 
- MCN with associated invasive carcinoma 
Intraductal papillary mucinous neoplasms (IPMN) 
- IPMN with low or intermediate grade dysplasia 
- IPMN with high grade dysplasia 
- IPMN with associated invasive carcinoma 
Intraductal oncocytic papillary neoplasms (IOPN) 
 
Intraductal tubular neoplasms 
Cystic acinar neoplasms 
- Acinar cell cystadenoma 
- Acinar cell cystadenocarcinoma 
Solid 
Invasive pancreatic ductal adenocarcinoma (and its 
variants) 
- Tubular adenocarcinoma 
- Adenosquamous carcinoma 
- Colloid carcinoma 
- Medullary carcinoma 
- Hepatoid carcinoma 
- Signet ring cell carcinoma 
- Undifferentiated carcinoma 
- Undifferentiated carcinoma with osteoclast-like giant 
cells 
Acinar cell carcinoma 
Neuroendocrine neoplasms 
- Neuroendocrine microadenoma 
- Neuroendocrine tumors (NET) 
-- NET G1 
-- NET G2 
-- Neuroendocrine carcinoma (NEC) 
--- Small cell NEC 
--- Large cell NEC 
-- Functional NETs (associated with clinical syndrome) 
--- Insulinoma 
--- Gastrinoma 
--- Glucagonoma 
--- Serotonin-producing NET 
--- Somatostatinoma 
--- VIPoma 
Mixed tumors (combined acinar, ductal and/or 
endocrine differentiation) 
Solid-pseudopapillary neoplasms (SPN) 
Pancreatoblastoma 
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Non-epithelial tumors (rare) 
Mesenchymal tumors (various histologies, benign or 
malignant) 
Lymphangioma 
Lymphoma 
Mature cystic teratoma 
Secondary tumors (including metastasis) 
Non-neoplastic tumors and other lesions presenting 
as masses (partial list) 
Cystic 
- Groove pancreatitis (paraampullary duodenal wall 
cyst) 
- Pancreatic pseudocyst 
- Ductal retention cyst 
- Congenital cyst 
- Foregut cyst 
- Lymphoepithelial cyst 
Solid 
- Chronic pancreatitis 
- Lymphocytic sclerosing pancreatitis (autoimmune 
pancreatitis) 
- Heterotopic spleen 
Clinics and pathology 
Note 
The vast majority of malignant pancreatic tumors 
(>85%) are pancreatic ductal adenocarcinomas 
(PDAC), the focus of this section. 
Etiology 
An evolving consensus arising from lineage tracing 
studies in animal models implicate acinar cells (and not 
ductal epithelium) as the likely cell of origin for PDAC. 
Precursor pancreatic intraepithelial neoplasia (PanIN) 
lesions have been shown to arise in the context of 
inflammation and acinar cell injury through a 
transitional process referred to as acinar-to-ductal 
metaplasia (ADM). ADM and PanIN formation is 
facilitated by oncogenic KRAS2 in combination with 
other molecular events and contributing factors (Morris 
et al., 2010). The concept of chronic inflammation and 
injury to the pancreas as an inciting event and/or 
promoter of pancreatic cancer progression is bolstered 
by the significantly increased (50-80 fold) risk of 
PDAC seen in patients with hereditary pancreatitis, as 
well as an increased risk for PDAC associated with the 
occurrence of chronic pancreatitis in the general 
population. 
Epidemiology 
The vast majority of PDAC arises sporadically. Age is 
a significant factor linked to the development of 
pancreatic cancer, with more than 80% of cases 
occurring after 60 years of age and only rare cases 
before the age of 40. Various dietary, lifestyle and 
environmental factors have been correlated with an 
increased risk for PDAC. A partial list of risk factors 
includes cigarette smoking, diets high in fat and total 
calories, obesity, prior gastrectomy and certain 
occupational (i.e., coal gas and metal workers) and 
chemical exposures (i.e., benzidine, solvents, DDT and 
gasoline). Diets high in fruits and vegetables, folate and 
vitamin C are reported to be protective. Chronic 
pancreatitis and longstanding diabetes mellitus are also 
linked to an increased risk of pancreatic cancer (Yadav 
and Lowenfels, 2013). The development of chronic 
pancreatitis or adult-onset diabetes mellitus has been 
shown to be temporally linked to an increased risk for 
the subsequent development of PDAC, although it is 
unclear to what extent these events represent preceding 
causal factors as opposed to early manifestations of 
clinically undetected or nascent PDAC. 
Approximately 10% of PDAC have familial 
inheritance, although only a minority (~20%) of 
familial PDAC has been linked to a known genetic 
syndrome or causal gene mutation. Hereditary 
syndromes associated with familial pancreatic cancer 
(along with their cumulative lifetime risk for 
developing PDAC by age 70) include: FAP (5%), 
hereditary breast and ovarian cancer associated with 
BRCA1/BRCA2 (5%), Lynch syndrome (<5%), 
FAMMM (17%), Peutz-Jeghers (36%), as well as 
cystic fibrosis (<5%) and hereditary pancreatitis (40%) 
linked to PRSS1 and SPINK1. (Templeton and 
Brentall, 2013). 
Clinics 
Clinical presentation is often non-specific for PDAC, 
which along with a lack of a viable early screening 
strategy for the general population, contributes to the 
late detection of disease in many patients. Some 
common presenting symptoms include epigastric pain 
radiating to the back, weight loss, jaundice and/or light 
colored stools (more typically for tumors in the head of 
the pancreas), digestive problems, anorexia, nausea, 
pancreatitis-related symptoms, new-onset diabetes and 
even depression. Diagnostic imaging techniques 
include computerized tomography (with PDAC 
commonly presenting as hypodense mass with possible 
pancreatic and/or bile duct dilation), endoscopic 
ultrasound or endoscopic retrograde 
cholangiopancreatography (ERCP). 
Pathology 
Precursor lesions that can give rise to invasive PDAC 
include pancreatic intraepithelial neoplasia (PanIN), 
IPMN and MCN. A majority of invasive PDAC arises 
from PanIN, dysplastic ductal proliferations showing 
variable epithelial atypia. PanINs are typically not 
recognized grossly and are generally smaller than 0.5 
cm. Most IPMNs tend to be greater than 1.0 cm in size. 
A consensus classification system for PanIN lesions 
based on increasing cytologic atypia has been adopted 
(PanIN1A, 1B, 2 or 3). There is a parallel stepwise 
accumulation of molecular events found in PDAC 
associated with increasing PanIN grade (Hruban et al., 
2001). IPMN are cystic or solid mass forming lesions 
Pancreatic tumors: an overview Tirado CA, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(2) 127 
arising within the ductal tree itself, typically associated 
with abundant mucin production and demonstrating a 
papillary growth pattern of columnar epithelium of 
gastric foveolar, intestinal and/or pancreaticobiliary 
differentiation. IPMNs involving the main pancreatic 
duct (main-duct type) versus those isolated to side-
branch ducts (branch-duct type) are distinguished 
clinically because of a higher risk of malignant 
progression associated with the former. Unlike IPMN, 
MCNs are mucinous cyst-forming lesions that do not 
communicate with the ductal system. MCNs almost 
exclusively occur in women (>95%) and arise at a 
median age of 40-50 years. The histologic sine qua non 
for MCNs is their distinctive ovarian-type stroma 
(Basturk et al., 2009). 
Most PDAC are solid tumors and arise in the head of 
the pancreas (~70%), with the remainder occurring in 
either the body and/or the tail of the pancreas. Many 
PDACs invade beyond the pancreas itself to involve 
peripancreatic soft tissues with variable direct 
extension into adjacent anatomic structures, which 
depending on the location of the primary tumor may 
include the bile duct, ampulla, small or large bowel, 
peritoneum, stomach and spleen (pT3). Involvement of 
the celiac axis or mesenteric artery constitutes locally 
advanced disease (pT4). Common sites of distant 
metastatic spread include the liver and lungs, although 
nearly every other organ site has been shown to be 
involved at lesser frequencies. Histologically, PDAC 
presents as haphazard growth pattern of invasive glands 
that provoke an intense desmoplastic 
fibroinflammatory stromal reaction; this robust stromal 
reaction facilitates tumor cell growth and acts as a 
significant barrier to effective drug delivery (Feig et al., 
2012). PDAC infiltrates along existing duct, nerve and 
vessel structures to aggressively invade the pancreas 
and surrounding tissues. Histologic grade is most 
commonly based on the degree of gland formation, 
although other criteria (i.e., mitotic activity, nuclear 
atypia, etc.) have also been proposed as alternatives. 
Treatment 
PDAC is notoriously resistant to chemotherapy, with 
only modest survival benefits realized in the adjuvant 
or neoadjuvant setting. Until recently, single agent 
chemotherapy (gemcitabine or 5-FU) was the standard 
chemotherapy regimen employed in either early stage 
or advanced pancreatic cancer. Radiation therapy has 
remained a subject of some controversy and its use 
varies depending on institution. Recent advances 
include the use of multi-agent cytotoxic chemotherapy, 
as well as the addition of agents targeting specific 
molecular pathways (i.e., EGFR inhibition) or the 
tumor stroma, which have resulted in improved 
survival outcomes in clinical trials and are now being 
widely adopted as standard of care for patients able to 
tolerate these regimens (Paulson et al., 2013). 
Prognosis 
PDAC accounts for over 220000 annual deaths 
worldwide, with five year survival for all PDAC 
patients reported to be 5-6% (Raimondi et al., 2009). 
Most PDAC patients present with non-operative, 
locally advanced (AJCC Stage III) or metastatic (AJCC 
Stage IV) disease. Fewer than 20% of patients present 
with resectable disease (AJCC Stage I or II). Overall 
five year survival is still only 15-20% for early stage 
patients following successful R0 surgical resection, 
primarily due to metastatic or recurrent local disease 
(Paulson et al., 2013). This suggests a large percentage 
of resected patients have clinically unrecognized 
systemic disease at the time of surgery. Important 
prognostic factors include initial stage, with 
significantly improved survival for patients who 
undergo resection. Factors impacting survival in the 
setting of resection include margin status, tumor size, 
histologic grade and lymph node involvement 
(Hidalgo, 2010). 
Genetics 
Note 
Conventional and molecular cytogenetic analyses of 
PDAC have demonstrated significant intratumor 
cytogenetic heterogeneity (ICH), with complex 
cytogenetic abnormalities and extensive multiclonality. 
Extensive ICH in PDAC has been shown to correlate 
with a more dismal prognosis than those with less 
complex cytogenetic abnormalities (Heim and 
Mitelman, 2009). 
Cytogenetics 
Cytogenetics Morphological 
Conventional cytogenetic analysis has revealed the 
following numerical aberrations to be associated with 
PDAC: -4, -6, +7, -9, +11, -12, -13, -17, -18, +20, -21, -
22, -X and -Y. The most common losses in the 
aforementioned aneuplodies are -18, -17, and -21 and 
the most common gains are +7 and +20. Balanced and 
unbalanced structural aberrations revealed by 
cytogenetic analysis include chromosomal arms 1p, 1q, 
3p, 3q, 5p, 6p, 6q, 7q, 8q, 8p, 9p, 11q, 11p, 12p, 15q, 
17p, 17q, 18q, 19p, 19q, 20p, and 20q (Heim and 
Mitelman, 2009). 
Cytogenetics Molecular 
Molecular cytogenetic techniques most commonly 
utilized in the analysis of PDAC published in current 
literature include fluorescence in situ hybridization 
(FISH), comparative genomic hybridization (CGH), 
single nucleotide polymorphism (SNP) arrays, spectral 
karyotyping (SKY), whole-genome sequencing, etc. 
CGH analysis applied to malignant PDAC cell lines has  
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elucidated regions of significant copy number 
aberrations. Gains of the long arms of chromosomes 
11, 8, 3, and 1, as well as losses of 18q, 17p, and 8p 
were reported to have been the most commonly altered 
regions. Further analysis showed that the following 
chromosomal bands/regions were most affected by 
copy number aberrations: 8q24.2-q24.3, 8q21-qter, 
3q23-qter, and 14q11.2-qter (Griffin et al., 2007). 
SNP array analyses have revealed significant gains at 
chromosomal bands 1q21.2-q21.3, 7q36.3, 8q24.3, and 
20q13.32-q13.33, as well as significant losses at bands 
1p35.3, 9p22.3, 12q23.1, 17p12-p13.3, and 18q21.2. 
Furthermore, loss of heterozygosity (LOH) has been 
identified at significant amounts on chromosomal 
bands spanning 9p21.2-p24.1, 17p11.2-q13.3, and 
18q12.1-q12.3 (Gutierrez et al., 2011; Willis et al., 
2012). The aforementioned bands are also loci of genes 
implicated in the genesis of a number of solid-organ 
and hematological malignancies (for example, 
CDKN2A and SMAD4). 
Genes involved and proteins 
Note 
A number of genes have been implicated or are 
suspects in the etiology of PDAC; however, precise 
diagnostic and prognostic significance has not been 
established for most, which require further 
investigation as to their specific roles in pancreatic 
carcinogenesis and usefulness as prognostic or 
predictive biomarkers.  
Exomic sequencing reveals PDAC tumors average 
greater than 60 genetic alterations, which includes of a 
small number of key driver genes mutated at high 
frequency (KRAS2, TP53, CDKN2A and SMAD4) 
along with a far larger number of heterogenous genes 
mutated at lower frequency across the full spectrum of 
patients (Jones et al., 2008). 
KRAS2 
Location 
12p12.1 
Note 
KRAS2 mutations have been implicated in > 95% of 
PDAC. Observed in early PanIN lesions and capable of 
driving PanIN and PDAC formation in genetically 
engineered mouse models, oncogenic mutation of 
KRAS2 is a bona fide early or initiating event for 
PDAC carcinogenesis (Iacobuzio-Donahue, 2012; 
Iacobuzio-Donahue et al., 2012). Mutations most 
commonly occur at codons 12 (54-74%), 13 (3-5%), 
and 61 (3-5%) (Schultz et al., 2012). 
Protein 
KRAS2 codes for the ubiquitous RAS protein, which is 
found on the plasma membrane and mediates GTP-
mediated signal transduction pathways involved in cell 
proliferation, survival and motility, among others. 
TP53 
Location 
17p13.1 
Note 
TP53 mutations have been implicated in up to 75% of 
pancreatic cancers and typically arise in later stage 
PanIN lesions (Iacobuzio-Donahue, 2012; Iacobuzio-
Donahue et al., 2012). 
Protein 
TP53 acts as a tumor suppressor gene and codes for the 
ubiquitously expressed p53 protein, which acts as 
multifunctional protein involved in regulating cell cycle 
progression, senescence, DNA repair and apoptosis. 
CDKN2A 
Location 
9p21.3 
Note 
CDKN2A inactivation has been implicated in > 95% of 
pancreatic cancers via a number of mechanisms 
including genetic deletion and promoter DNA 
hypermethylation gene silencing.  
It is commonly inactivated at an intermediate stage of 
PanIN progression (Iacobuzio-Donahue, 2012). 
Protein 
CDKN2A is a tumor suppressor gene that codes for the 
P16-INK4a protein, which functions to inhibit cell 
cycle progression at the G1-S checkpoint. 
SMAD4 
Location 
18q21.2 
Note 
SMAD4 is mutated in up to 55% of pancreatic cancers 
and typically arise in later stage PanIN lesions or 
invasive PDAC (Iacobuzio-Donahue, 2012).  
SMAD4 inactivation/protein loss is a prognostic 
marker associated with increased metastatic activity in 
pancreatic malignancies and thus portends worse 
prognosis (Iacobuzio-Donahue et al., 2012). 
Protein 
SMAD4 codes for a namesake protein that is 
ubiquitously expressed and functions mainly in TGF-
beta signaling.  
The actions of the Smad4 protein recruit other proteins 
in the Smad family and synergistically affect 
transcription by modifying DNA-binding proteins. 
ATM 
Location 
11q22.3 
Note 
ATM mutations (generally germline mutations) have 
been implicated in 2.5% of cases of familial pancreatic 
cancer and 8% of non-familial pancreatic cancer cases  
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(Iacobuzio-Donahue et al., 2012). ATM has been 
identified as a prominent susceptibility gene in 
pancreatic malignancies as well, causing a five-fold 
increase in the risk of pancreatic cancer development in 
individuals with ATM aberrations (Roberts and Klein, 
2012). 
Protein 
ATM codes for a protein that is ubiquitously expressed 
and functions in cell-cycle regulation (checkpoint 
initiation) by phosphorylating a number of regulatory 
proteins (for example, p53 and BRCA1).  
ATM also functions in DNA repair and damage control 
associated signaling pathways. 
BRCA1 
Location 
17q21.31 
Note 
BRCA1 mutations are most attributed to familial 
pancreatic cancer, and are observed in approximately 
3.7% of cases (Iqbal et al., 2012). BRCA1 is 
considered a susceptibility gene, and aberrations have 
been observed to increase pancreatic cancer 
development by 2.2-fold.  
The gene has also been a target of PARP inhibitors and 
DNA cross-linking agents in clinical trials (Roberts and 
Klein, 2012). 
Protein 
BRCA1 codes for a ubiquitously expressed namesake 
protein that functions mainly in DNA repair and 
damage control, cell-cycle regulation, ubiquitination, 
transcription regulation, etc. Mutations have been 
observed to arise via changes to the primary DNA 
sequence.  
Epigenetic events (usually aberrant methylation) can 
also contribute to its dysregulation. 
TGFBR2 
Location 
3p24.1 
Note 
TGFBR2 mutations are implicated in 4.1% of 
pancreatic cancer cases (Goggins et al., 1998). 
Comprehensive pathway-based analysis of genome-
wide association studies finds 43 pancreatic cancer 
related single-nucleotide polymorphisms (SNPs) in the 
TGFBR2 gene, and highlights 2 SNPs within the 
Th1/Th2 immune response pathway (Li et al., 2012). 
 
Protein 
TGFBR2 codes for a member of the transmembrane 
serine/threonine kinase family receptor of TGF-β. 
TGFBR2 mediates TGF-β cell signaling to regulate cell 
differentiation and proliferation. 
TSC2 
Location 
16p13.3 
Note 
Inactivation mutations of TSC2 have been observed in 
8.8% of pancreatic neuroendocrine tumor cases (Jiao et 
al., 2011).  
Many signal inputs, such as growth factors, energy 
availability and Wnt signaling converge with TSC2 to 
regulate mTOR signaling (Dazert and Hall, 2011).  
Loss of tuberin expression by immunohistochemistry 
has been described to occur in more than 50% of 
PDAC as well (Kataoka et al., 2005). 
Protein 
TSC2 codes for a cytoplasmic protein that is widely 
expressed and is thought to function in GTPase 
activation and regulation as well as negative regulation 
of the mTOR pathway. 
BRCA2 
Location 
13q13.1 
Note 
BRCA2 has been established as a familial pancreatic 
cancer gene and mutations of it have been observed in 
6.1% of cases of familial pancreatic cancer (Iqbal et al., 
2012). This gene has been the subject of PARP 
inhibitors and DNA cross-linking agents, which can 
potentially provide viable therapeutic agents for 
pancreatic malignancies (Iacobuzio-Donahue et al., 
2012). 
Protein 
BRCA2 codes for a namesake, ubiquitously expressed 
nuclear protein and functions mainly in DNA repair 
and damage control; however, it possesses less major 
roles in cell-cycle checkpoint and transcription 
regulation. 
PALB2 
Location 
16p12.2 
Note 
PALB2 has been reported as a familial pancreatic 
cancer gene. The truncated PALB2 protein has been 
observed in 3.1% of familial pancreatic cancer cases 
(Jones et al., 2009). 
Protein 
PALB2 is a tumor suppressor gene that codes for a 
namesake nuclear protein and forms a complex with  
BRCA1 and BRCA2 which plays an essential role in 
homologous recombination DNA repair. 
PTEN 
Location 
10q23.31 
Note 
PTEN mutations are implicated in up to 7.3% of 
pancreatic neuroendocrine tumor cases and individuals 
that possess such mutations (as well as mutations in 
TSC2 (8.8% of cases) and PIK3CA (1.4% of cases)) 
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could potentially be responsive to agents that inhibit the 
mTOR pathway regulated by the aforementioned genes 
(Iacobuzio-Donahue et al., 2012). Although PTEN 
mutations are only rarely detected in PDAC, its loss of 
function in PDAC has been attributed to a number of 
other mechanisms including promoter 
hypermethylation gene silencing and other pathway 
alterations including changes in AKT expression. 
Protein 
PTEN codes for a namesake, widely expressed 
cytoplasmic protein that functions in phosphatase 
regulation and tumor suppression. 
BRAF 
Location 
7q34 
Note 
BRAF mutations have been implicated in 16% of 
PDAC cases (Schultz et al., 2012). In intraductal 
papillary mucinous neoplasms (IPMNs) of the 
pancreas, missense mutations within exon 15 have been 
found in 2.7% cases (Schonleben et al., 2007). So far, 
no BRAFV600E mutation has been observed in 
pancreatic cancer. 
Protein 
BRAF codes for a namesake protein belonging to the 
raf family of serine/threonine protein kinases. The 
RAS/BRAF/MEK/ERK pathway functions in cell 
apoptosis, proliferation and differentiation. 
AKT2 
Location 
19q13.1-q13.2 
Note 
AKT2 amplification has been implicated in 20% of 
PDAC samples (Ruggeri et al., 1998). 32-43% of 
PDAC samples showed a high intensity of AKT2 
(Altomare et al., 2002; Yamamoto et al., 2004). 
Overexpression of AKT2 is sufficient for the metastasis 
of PDAC (Ruggeri et al., 1998). The mechanisms for 
AKT2 overexpression in pancreatic cancer involve 
PTEN loss and/or PI3K activation (Altomare et al., 
2002). 
Protein 
AKT2 codes for a namesake protein belonging to a 
subfamily of serine/threonine kinases containing SH2-
like domains. AKT2 functions to promote cancer cell 
survival, migration, and invasion. Akt2 is also an 
important signaling molecule in the insulin signaling 
pathway. 
ARID1A 
Location 
1p35.3 
Note 
ARID1A is the likely target of 1p36.11 deletion 
observed in pancreatic malignancies (Shain et al., 
2012).  
ARID1A mutations have been implicated in 8% of 
pancreatic cancers, including nonsense and indel 
mutations (Jones et al., 2012).  
The internal duplication of ARID1A exons 2-4 in 
PANC1 cells has been reported (Shain et al., 2012). 
Protein 
The protein encoded by ARID1A is a key component 
of the highly conserved SWI-SNF chromatin 
remodeling complex.  
It specifically binds an AT-rich DNA sequence and 
facilitates transcription. 
MLH1 
Location 
3p21.3 
Note 
26% of the PDAC showed microsatellite instability 
(MSI), 23% of which also showed hypermethylation of 
the promoter of MLH1 (Yamamoto et al., 2001). In 
another study, the MLH1 hypermethylation rate was 
4% in pancreatic carcinomas. 
Protein 
MLH1 codes for a protein that plays an essential role in 
DNA mismatch repair along with a set of genes known 
as mismatch repair genes. 
STK11 
Location 
19p13.3 
Note 
Germline mutations in the STK11 gene are found in 
~70% of Peutz-Jeghers syndrome (PJS) cases (Volikos 
et al., 2006; Aretz et al., 2005; Chow et al., 2006).  
The mutation can be a point mutation or the deletion of 
parts of the gene. For PJS patients, the cumulative risk 
for pancreatic cancer is 26% at age of 70 (Korsse et al., 
2013). 
Protein 
Human STK11 encodes for the LKB1 protein that is 
expressed in all human tissues (Rowan et al., 2000). 
STK11 is a tumor suppressor gene since it can 
negatively regulate the activity of mTOR complex 1 
(mTORC1) (Dazert and Hall, 2011). STK11 also 
functions in cell cycle arrest, p53 mediated apoptosis, 
Wnt signaling and TGF-beta signaling. 
To be noted 
Note 
Some data regarding precise loci, proteins, and 
functions of the aforementioned genes relevant to 
pancreas tumors was gathered from the Atlas of 
Genetics and Cytogenetics in Oncology and 
Haematology database. 
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